Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant

References

1. Arico E., Robertson K., Allen D., Ferrantini M., Belardelli F., Nash A. A. 2002; Humoral immune response and protection from viral infection in mice vaccinated with inactivated MHV-68: effects of type I interferon. J Interferon Cytokine Res 22:1081–1088
   [Google Scholar]
2. Asano Y., Takahashi M. 1977; Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children. Pediatrics 60:810–814
   [Google Scholar]
3. Binne U. K., Amon W., Farrell P. J. 2002; Promoter sequences required for reactivation of Epstein–Barr virus from latency. J Virol 76:10282–10289
   [Google Scholar]
4. Blasdell K., McCracken C., Morris A., Nash A. A., Begon M., Bennett M., Stewart J. P. 2003; The wood mouse is a natural host for Murid herpesvirus 4. J Gen Virol 84:111–113
   [Google Scholar]
5. Brooks J. M., Croom-Carter D. S., Leese A. M., Tierney R. J., Habeshaw G., Rickinson A. B. 2000; Cytotoxic T-lymphocyte responses to a polymorphic Epstein–Barr virus epitope identify healthy carriers with coresident viral strains. J Virol 74:1801–1809
   [Google Scholar]
6. Christensen J. P., Doherty P. C. 1999; Quantitative analysis of the acute and long-term CD4(+) T-cell response to a persistent gammaherpesvirus. J Virol 73:4279–4283
   [Google Scholar]
7. Coleman H. M., de Lima B., Morton V., Stevenson P. G. 2003; Murine gammaherpesvirus 68 lacking thymidine kinase shows severe attenuation of lytic cycle replication in vivo but still establishes latency. J Virol 77:2410–2417
   [Google Scholar]
8. Doherty P. C., Tripp R. A., Hamilton-Easton A. M., Cardin R. D., Woodland D. L., Blackman M. A. 1997; Tuning into immunological dissonance: an experimental model for infectious mononucleosis. Curr Opin Immunol 9:477–483
   [Google Scholar]
9. Epstein M. A., Morgan A. J., Finerty S., Randle B. J., Kirkwood J. K. 1985; Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318:287–289
   [Google Scholar]
10. Liu L., Usherwood E. J., Blackman M. A., Woodland D. L. 1999; T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice. J Virol 73:9849–9857
    [Google Scholar]
11. May J. S., Coleman H. M., Smillie B., Efstathiou S., Stevenson P. G. 2004; Forced lytic replication impairs host colonization by a latency-deficient mutant of murine gammaherpesvirus-68. J Gen Virol 85:137–146
    [Google Scholar]
12. Sitki-Green D., Covington M., Raab-Traub N. 2003; Compartmentalization and transmission of multiple Epstein–Barr virus strains in asymptomatic carriers. J Virol 77:1840–1847
    [Google Scholar]
13. Stevenson P. G., Doherty P. C. 1999; Non-antigen-specific B-cell activation following murine gammaherpesvirus infection is CD4 independent in vitro but CD4 dependent in vivo . J Virol 73:1075–1079
    [Google Scholar]
14. Stevenson P. G., Belz G. T., Castrucci M. R., Altman J. D., Doherty P. C. 1999a; A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope. Proc Natl Acad Sci U S A 96:9281–9286
    [Google Scholar]
15. Stevenson P. G., Cardin R. D., Christensen J. P., Doherty P. C. 1999b; Immunological control of a murine gammaherpesvirus independent of CD8+ T cells. J Gen Virol 80:477–483
    [Google Scholar]
16. Stevenson P. G., Belz G. T., Altman J. D., Doherty P. C. 1999c; Changing patterns of dominance in the CD8+ T cell response during acute and persistent murine gamma-herpesvirus infection. Eur J Immunol 29:1059–1067
    [Google Scholar]
17. Stevenson P. G., Boname J. M., de Lima B., Efstathiou S. 2002a; A battle for survival: immune control and immune evasion in murine gamma-herpesvirus-68 infection. Microbes Infect 4:1177–1182
    [Google Scholar]
18. Stevenson P. G., May J. S., Smith X. G., Marques S., Adler H., Koszinowski U. H., Simas J. P., Efstathiou S. 2002b; K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol 3:733–740
    [Google Scholar]
19. Stewart J. P., Janjua N. J., Pepper S. D., Bennion G., Mackett M., Allen T., Nash A. A., Arrand J. R. 1996; Identification and characterization of murine gammaherpesvirus 68 gp150: a virion membrane glycoprotein. J Virol 70:3528–3535
    [Google Scholar]
20. Stewart J. P., Micali N., Usherwood E. J., Bonina L., Nash A. A. 1999; Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination. Vaccine 17:152–157
    [Google Scholar]
21. Sun R., Lin S. F., Gradoville L., Yuan Y., Zhu F., Miller G. 1998; A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 95:10866–10871
    [Google Scholar]
22. Sunil-Chandra N. P., Arno J., Fazakerley J., Nash A. A. 1994; Lymphoproliferative disease in mice infected with murine gammaherpesvirus 68. Am J Pathol 145:818–826
    [Google Scholar]
23. Tibbetts S. A., McClellan J. S., Gangappa S., Speck S. H., Virgin H. W. 2003; Effective vaccination against long-term gammaherpesvirus latency. J Virol 77:2522–2529
    [Google Scholar]
24. Usherwood E. J., Ward K. A., Blackman M. A., Stewart J. P., Woodland D. L. 2001; Latent antigen vaccination in a model gammaherpesvirus infection. J Virol 75:8283–8288
    [Google Scholar]
25. Walling D. M., Brown A. L., Etienne W., Keitel W. A., Ling P. D. 2003; Multiple Epstein–Barr virus infections in healthy individuals. J Virol 77:6546–6550
    [Google Scholar]
26. Wills M. R., Carmichael A. J., Sissons J. G. 2002; Vaccines against persistent DNA virus infections. Br Med Bull 62:125–138
    [Google Scholar]
27. Wu T. T., Usherwood E. J., Stewart J. P., Nash A. A., Sun R. 2000; Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency. J Virol 74:3659–3667
    [Google Scholar]